18/🔬TROPHY-U-01 Cohort 3 trial safety of sacituzumab govitecan👇

TRAEs led to➡️
✋SG interruptions in 46%
⬇️SG dose reduction in 39%
🛑SG d/c in 15%
@markuseckstein3.bsky.social @amandanizammd.bsky.social #OncSky

11/Erda. Safety
Grade ≥3 TRAEs occurred in 45.9% w erdafitinib & 46.4% w chemo

⚖️Most AEs w erdafitinib manageable w dose modification & best supportive care
🛑Tx d/c rates 8.1% w erdafitinib & 13.4% w chemo
#OncSky #BladderCancer

10/➡️Erdafitinib cont.
👍mOS and mPFS significantly ⬆️in erdafitinib group vs taxane or vinflunine

THOR1 trial efficacy results 👇
#OncSky @achoud72.bsky.social @pbarata95.bsky.social @crisbergerot.bsky.social @paulobergerot.bsky.social @alisonbirtle.bsky.social @laurabukavinamd.bsky.social

7/ IMvigor130 safety results 👇

🎯 Fewer AEs ➡️ withdrawal of any agent in atezo only group
🎯 Most common TRAEs mainly related to chemo
✓ Anemia
✓ Neutropenia
✓ Thrombocytopenia
#OncSky

6/Atezolizumab EMA approved as monotx
✓1L in cisplatin-ineligible + PD-L1 +ve
Based on IMvigor 210 & 130 trials

🔬IMvigor 130:
✅mPFS significantly longer in atezo+plat/Gem vs plat/Gem alone
🚫mOS not sign. longer in atezo grps vs plat/Gem alone
@oncobellmunt.bsky.social @sandysrimd.bsky.social

2/ 📸👇COI & CME info👇
Full #CME ℹ️ bit.ly/muc_tw2
1️⃣ Answer Pre-survey 👉 bit.ly/muc_tw2_pre
2️⃣ Review #MedTweetorial👇
3️⃣ claim CME🏆bit.ly/muc_tw2_post

#MedTwitter #OncTwitter #gucsm #BladderCancer #MetastaticUrothelialCarcinoma #OncX #CommunityOncology

Stayed active during 17-hour flight from SEA->Singapore :-) Looking forward to present TROPiCS04 phase 3 trial data at #ESMOASIA on Dec 7 ~10am local time discussed by Dr. Friedlander @oncoalert.bsky.social @achoud72.bsky.social @erplimackmd.bsky.social @valdesan.bsky.social @fredhutch.bsky.social

This is my 1st post in BlueSky wishing Happy Thanksgiving to everyone with health! Best wishes from Vienna!
@erplimackmd.bsky.social @achoud72.bsky.social @lauracaba.bsky.social @oncoalert.bsky.social @johngoremd.bsky.social @drnataliagandur.bsky.social @fredhutch.bsky.social @tmprowell.bsky.social